March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
1 citations
,
November 2016 in “Journal of the Dermatology Nurses’ Association” Finasteride treats hair loss but may cause side effects like low libido and dizziness.
September 2013 in “Nature Reviews Urology” 14 citations
,
January 2003 in “Actas Urológicas Españolas” Finasteride effectively reduces symptoms of enlarged prostate with minimal side effects.
2 citations
,
January 2011 in “Yearbook of Urology” Stopping finasteride can improve sperm count in infertile men.
3 citations
,
October 1993 in “Endocrinology”
20 citations
,
May 2018 in “The Journal of Urology” Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.
September 2025 in “Cureus” Equilibrium dialysis can accurately measure testosterone levels when lab results are inconsistent.
May 2012 in “Reactions Weekly” A man developed hair loss from testosterone treatment but improved with additional medication.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
2 citations
,
December 2017 in “Theriogenology” Testosterone increases acidification in the vas deferens by up-regulating V-ATPase.
2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
49 citations
,
January 1980 in “Journal of Cardiovascular Pharmacology” Minoxidil doesn't increase pericardial disorder risk, but may cause fluid accumulation.
Minoxidil and nebivolol can help prevent aortic aging in diabetic mice.
The FDA did not approve a testosterone drug because of safety concerns.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
June 2025 in “ACS Materials Letters” 55 citations
,
June 2012 in “Steroids” Testosterone affects vascular cells directly without converting to estradiol.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
January 2023 in “The Annals of african surgery” Hormone treatment before hypospadias surgery can increase penis size and reduce surgery complications.
July 2025 in “Saudi Journal of Medicine and Public Health” 5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
2 citations
,
March 2025 in “Lynchburg Journal of Medical Science” Testosterone is important for women's health, but more research is needed to guide its use.
October 2024 in “Journal of the Endocrine Society” Feminizing hormone therapy increases kidney filtration rate.
May 2024 in “The journal of sexual medicine” Finasteride treatment may cause erectile dysfunction, but stopping it reverses these effects.
28 citations
,
May 1994 in “The Journal of Urology” Topical minoxidil not effective for erectile dysfunction treatment.
32 citations
,
April 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
Adherence to finasteride treatment for prostate issues is generally low.